A61K 31/7068
Having oxo groups directly attached to the pyrimidine ring
Official title: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K31/7068 (Having oxo groups directly attached to the pyrimidine ring) appears on 2,588 US grants and 5,142 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,588
- Published applications
- 5,142
- Assignees
- 1,854
- Inventors
- 8,554
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 6 | 0 |
| 1997 | 24 | 0 |
| 1998 | 24 | 0 |
| 1999 | 33 | 0 |
| 2000 | 22 | 0 |
| 2001 | 32 | 13 |
| 2002 | 27 | 54 |
| 2003 | 29 | 73 |
| 2004 | 15 | 87 |
| 2005 | 28 | 122 |
| 2006 | 41 | 134 |
| 2007 | 27 | 118 |
| 2008 | 26 | 89 |
| 2009 | 49 | 123 |
| 2010 | 52 | 149 |
| 2011 | 63 | 139 |
| 2012 | 84 | 129 |
| 2013 | 99 | 243 |
| 2014 | 132 | 315 |
| 2015 | 138 | 258 |
| 2016 | 155 | 311 |
| 2017 | 165 | 326 |
| 2018 | 168 | 249 |
| 2019 | 179 | 300 |
| 2020 | 171 | 292 |
| 2021 | 155 | 322 |
| 2022 | 119 | 323 |
| 2023 | 147 | 307 |
| 2024 | 141 | 259 |
| 2025 | 125 | 236 |
| 2026 | 97 | 171 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for treating pancreatic cancer and other solid tumors6 Oct 2026US 12,751,991 B2Lisata Therapeutics, Inc.
- Method of predicting therapeutic response and prognosis of metastatic breast cancer to chemotherapeutic agents, and treating metastatic breast cancer6 Oct 2026US 12,753,447 B2Samsung Life Public Welfare Foundation
- Methods for X chromosome reactivation29 Sep 2026US 12,746,254 B2The Regents of the University of California
- Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability29 Sep 2026US 12,746,255 B2Societe des Produits Nestle S. A.
- Imidazole-based synthetic lipidoids for in vivo mRNA delivery into immune cells29 Sep 2026US 12,747,214 B2Trustees of Tufts College
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Anti-cancer treatments and methods of use thereof8 Oct 2026US 2026/0308535 A1
- Methods for treating gastrointestinal inflammatory diseases using alpha-ketoglutarate (akg) modulators1 Oct 2026US 2026/0294856 A1
- Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine1 Oct 2026US 2026/0294948 A1Taiho Pharmaceutical Co., Ltd.
- Substituted bicyclic heterocycle compounds, compositions, and uses thereof1 Oct 2026US 2026/0294949 A1
Most cited
By later US patents
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Lineage-directed induction of human mesenchymal stem cell differentiation264US 5,736,396 ACase Western Reserve University · 1998
- Lineage-directed induction of human mesenchymal stem cell differentiation212US 5,942,225 ACase Western Reserve University · 1999
- Prodrugs phosphorus-containing compounds200US 6,312,662 B1Metabasis Therapeutics, Inc. · 2001
- Methods and compositions for treating flaviviruses and pestiviruses187US 7,105,493 B2Idenix Pharmaceuticals, Inc. · 2006